Hillary Durstein
Family · Las Vegas, NVNPI 1699179226
Payments from drug & device makers
Across 451 payments — averaging $46.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$5K
- Dendreon Pharmaceuticals LLC$3K
- Telix Pharmaceuticals$2K
- Astellas Pharma US Inc$1K
- Sumitomo Pharma America, Inc.$1K
- Bayer$838
- plus $7K from 31 others
What the payments were for
- Speaking & faculty fees$2,66013%
- Travel & lodging$2,95014%
- Food & beverage$14,59570%
- Education$7243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 21 | $5,366 |
| Dendreon Pharmaceuticals LLC | 57 | $3,277 |
| Telix Pharmaceuticals | 19 | $1,797 |
| Astellas Pharma US Inc | 50 | $1,463 |
| Sumitomo Pharma America, Inc. | 56 | $1,313 |
| Bayer | 12 | $838 |
| Johnson & Johnson | 23 | $805 |
| Urogen Pharma, Inc. | 18 | $679 |
| Boston Scientific | 13 | $653 |
| Hollister Incorporated | 16 | $648 |
| Pfizer | 24 | $596 |
| Amgen | 12 | $368 |
| Myovant Sciences Inc. | 13 | $353 |
| AbbVie | 18 | $319 |
| Endo Pharmaceuticals Inc. | 13 | $306 |
| Urovant Sciences Inc | 14 | $258 |
| Myriad Genetic Laboratories, Inc. | 12 | $244 |
| Antares Pharma, Inc. | 13 | $239 |
| 180 Medical, Inc. | 7 | $185 |
| Medtronic | 1 | $164 |
| AstraZeneca | 4 | $163 |
| Progenics Pharmaceuticals, Inc. | 3 | $143 |
| Coloplast | 4 | $103 |
| Blue Earth Diagnostics | 5 | $101 |
| Verity Pharmaceuticals Inc. | 3 | $74 |
| EMD Serono, Inc. | 1 | $74 |
| Accord Healthcare, Inc. | 3 | $54 |
| Sun Pharmaceutical Industries Inc. | 2 | $51 |
| Palette Life Sciences, Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| Endo USA, Inc. | 2 | $41 |
| Tolmar Pharmaceuticals, Inc. | 2 | $39 |
| Tolmar, Inc. | 2 | $37 |
| Tempus AI, Inc | 1 | $30 |
| Bioprotect Medical, Inc. | 1 | $23 |
| Mission Pharmacal Company | 1 | $14 |
| Teleflex LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,929 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 36 | $562,895 |
| ErleadaApalutamide | 26 | $399,990 |
| Abiraterone Acetate | 37 | $122,702 |
| OrgovyxRelugolix | 16 | $43,284 |
| MyrbetriqMirabegron | 35 | $39,891 |
| GemtesaVibegron | 46 | $32,329 |
| Estradiol | 76 | $4,520 |
| Testosterone | 24 | $2,037 |
| Tamsulosin Hcl | 182 | $2,017 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 57 | $1,664 |
| Oxybutynin Chloride ErOxybutynin Chloride | 27 | $557 |
| Oxybutynin Chloride | 22 | $347 |
| Finasteride | 30 | $256 |
| Prednisone | 35 | $131 |
| Sildenafil Citrate | 15 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,463 | $602,78671 claims |
| Johnson & JohnsonErleada | $805 | $399,99026 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $1,313 | $75,61362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Kelly PapeshLas Vegas$44K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Bernard BlanksLas Vegas$26K
- Victoria HughesLas Vegas$19K
- Anuradha ThirumalaiLas Vegas$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.